Literature DB >> 29948654

The influence of blood phenylalanine levels on neurocognitive function in adult PKU patients.

A Bartus1, F Palasti1, E Juhasz1, E Kiss2, E Simonova2, Cs Sumanszki1, P Reismann3.   

Abstract

It is well known that hyperphenylalaninemia caused by phenylketonuria (PKU) negatively influences cognitive performance. Several tests have been used to study these functions. Until now, no universal, optimal tool has been developed for detecting PKU-caused brain dysfunctions. Using computerized neuropsychological tests during daily routine would be helpful for screening subclinical brain deficits in adult PKU patients. In a monocentric, cross-sectional study, adult patients with PKU (n = 46; median age = 29.5 years; female/male ratio = 21/25) were tested with the computerized Cambridge Cognition (CANTAB) test measuring neurocognitive functions. Patients were divided into two groups: The "on diet" group included patients whose blood Phe-level was under 600 μmol/l (n = 20), and the "loose diet" group included patients whose blood Phe-level was above 600 μmol/l (n = 26) at the examination time. The results of the PKU-affected individuals were compared with a healthy control group (n = 31; median age = 25 years; female/male ratio = 11/20). Compared with the control group, PKU patients had significantly worse test results in memory, problem-solving skills, and strategy. However, there were no significant differences in response speed or initial thinking time. There was no correlation between the blood Phe-level, tyrosine (Tyr)-level or Phe/Tyr ratio and the different cognitive test results. There were no significant differences in test results between the two PKU subgroups. Several cognitive functions measured by CANTAB are negatively influenced by hyperphenylalaninemia in adult PKU patients. However, response speed and initial thinking time were not impaired as seriously as other functions. Patients with lower Phe-levels failed to achieve better test results than patients whose Phe-levels were notably elevated.

Entities:  

Keywords:  CANTAB; Neurocognitive functions; Phenylalanine; Phenylketonuria; Protein-restricted diet

Mesh:

Substances:

Year:  2018        PMID: 29948654     DOI: 10.1007/s11011-018-0267-6

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  27 in total

1.  Cognitive profile and mental health in adult phenylketonuria: A PKU-COBESO study.

Authors:  Rianne Jahja; Stephan C J Huijbregts; Leo M J de Sonneville; Jaap J van der Meere; Amanda M Legemaat; Annet M Bosch; Carla E M Hollak; M Estela Rubio-Gozalbo; Martijn C G J Brouwers; Floris C Hofstede; Maaike C de Vries; Mirian C H Janssen; Ans T van der Ploeg; Janneke G Langendonk; Francjan J van Spronsen
Journal:  Neuropsychology       Date:  2017-03-20       Impact factor: 3.295

2.  Phenylketonuria in adulthood: a collaborative study.

Authors:  R Koch; B Burton; G Hoganson; R Peterson; W Rhead; B Rouse; R Scott; J Wolff; A M Stern; F Guttler; M Nelson; F de la Cruz; J Coldwell; R Erbe; M T Geraghty; C Shear; J Thomas; C Azen
Journal:  J Inherit Metab Dis       Date:  2002-09       Impact factor: 4.982

3.  Executive functioning and speed of processing in phenylketonuria.

Authors:  Shelley Channon; Caroline Mockler; Philip Lee
Journal:  Neuropsychology       Date:  2005-09       Impact factor: 3.295

Review 4.  Diet termination in children with phenylketonuria: a review of psychological assessments used to determine outcome.

Authors:  S E Waisbren; R R Schnell; H L Levy
Journal:  J Inherit Metab Dis       Date:  1980       Impact factor: 4.982

5.  Normal clinical outcome in untreated subjects with mild hyperphenylalaninemia.

Authors:  J Weglage; M Pietsch; R Feldmann; H G Koch; J Zschocke; G Hoffmann; A Muntau-Heger; J Denecke; P Guldberg; F Güttler; H Möller; U Wendel; K Ullrich; E Harms
Journal:  Pediatr Res       Date:  2001-04       Impact factor: 3.756

6.  Neurocognitive evidence for revision of treatment targets and guidelines for phenylketonuria.

Authors:  Rianne Jahja; Stephan C J Huijbregts; Leo M J de Sonneville; Jaap J van der Meere; Francjan J van Spronsen
Journal:  J Pediatr       Date:  2014-01-30       Impact factor: 4.406

Review 7.  Executive function in early-treated phenylketonuria: profile and underlying mechanisms.

Authors:  Shawn E Christ; Stephan C J Huijbregts; Leo M J de Sonneville; Desirée A White
Journal:  Mol Genet Metab       Date:  2010       Impact factor: 4.797

8.  A neuropsychological profile of off-diet adults with phenylketonuria.

Authors:  J J Moyle; A M Fox; M Bynevelt; M Arthur; J R Burnett
Journal:  J Clin Exp Neuropsychol       Date:  2007-05       Impact factor: 2.475

Review 9.  The metabolic and molecular bases of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency.

Authors:  Nenad Blau; Heidi Erlandsen
Journal:  Mol Genet Metab       Date:  2004-06       Impact factor: 4.797

10.  Long-Term Follow-Up of Cognition and Mental Health in Adult Phenylketonuria: A PKU-COBESO Study.

Authors:  Rianne Jahja; Francjan J van Spronsen; Leo M J de Sonneville; Jaap J van der Meere; Annet M Bosch; Carla E M Hollak; M Estela Rubio-Gozalbo; Martijn C G J Brouwers; Floris C Hofstede; Maaike C de Vries; Mirian C H Janssen; Ans T van der Ploeg; Janneke G Langendonk; Stephan C J Huijbregts
Journal:  Behav Genet       Date:  2017-08-03       Impact factor: 2.805

View more
  7 in total

Review 1.  Phenylketonuria.

Authors:  Francjan J van Spronsen; Nenad Blau; Cary Harding; Alberto Burlina; Nicola Longo; Annet M Bosch
Journal:  Nat Rev Dis Primers       Date:  2021-05-20       Impact factor: 52.329

2.  Saccadic reaction time and ocular findings in phenylketonuria.

Authors:  Susanne Hopf; Caroline Nowak; Julia B Hennermann; Irene Schmidtmann; Norbert Pfeiffer; Susanne Pitz
Journal:  Orphanet J Rare Dis       Date:  2020-05-25       Impact factor: 4.123

3.  Adult cognitive outcomes in phenylketonuria: explaining causes of variability beyond average Phe levels.

Authors:  Cristina Romani; Filippo Manti; Francesca Nardecchia; Federica Valentini; Nicoletta Fallarino; Claudia Carducci; Sabrina De Leo; Anita MacDonald; Liana Palermo; Vincenzo Leuzzi
Journal:  Orphanet J Rare Dis       Date:  2019-11-28       Impact factor: 4.123

4.  A systematic review of cognitive functioning in early treated adults with phenylketonuria.

Authors:  Denise Leonne Hofman; Claire Louise Champ; Clare Louise Lawton; Mick Henderson; Louise Dye
Journal:  Orphanet J Rare Dis       Date:  2018-08-30       Impact factor: 4.123

5.  A benefit-risk analysis of pegvaliase for the treatment of phenylketonuria: A study of patients' preferences.

Authors:  Sumitra SriBhashyam; Kevin Marsh; Adrian Quartel; Haoling H Weng; Ari Gershman; Nicola Longo; Janet Thomas; Roberto Zori
Journal:  Mol Genet Metab Rep       Date:  2019-08-30

6.  Cognitive Outcomes and Relationships with Phenylalanine in Phenylketonuria: A Comparison between Italian and English Adult Samples.

Authors:  Cristina Romani; Filippo Manti; Francesca Nardecchia; Federica Valentini; Nicoletta Fallarino; Claudia Carducci; Sabrina De Leo; Anita MacDonald; Liana Palermo; Vincenzo Leuzzi
Journal:  Nutrients       Date:  2020-10-03       Impact factor: 5.717

Review 7.  Similarities and differences in key diagnosis, treatment, and management approaches for PAH deficiency in the United States and Europe.

Authors:  Tracy Brock Lowe; Jane DeLuca; Georgianne L Arnold
Journal:  Orphanet J Rare Dis       Date:  2020-09-25       Impact factor: 4.123

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.